Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560313 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL12604928 | 0.89 | EPHX1 (0.37) | CES2EPHX1 | |
| SCHEMBL7732630 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL938022 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL938023 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL4152009 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL2157709 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL5438205 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL4155540 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL5464867 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2026-02-19 | — | — | US | claimed |
| US-20250352444-A1 | Antimicrobial mixtures | SYMRISE AG (DE) | 2025-11-20 | — | — | US | claimed |
| US-20250325463-A1 | COMPOSITIONS (III) | SYMRISE AG (DE) | 2025-10-23 | — | — | US | claimed |
| EP-4622621-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | Symrise AG (DE) | 2025-10-01 | — | — | EP | claimed |
| CN-119592371-A | Essence containing coffee and cocoa compound extract and preparation method thereof | 茂名华美实业有限公司 | 2025-03-11 | — | — | CN | claimed |
| EP-4472606-A1 | COMPOSITIONS (III) | Symrise AG (DE) | 2024-12-11 | — | — | EP | claimed |
| CN-118873543-A | Aerosol matrix, application thereof and aerosol generating device | 深圳芳芯科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-118873528-A | Nebulizable substrate, use thereof and aerosol generating device | 深圳芳芯科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-20240358611-A1 | COMPOSITIONS | SYMRISE AG (DE) | 2024-10-31 | — | — | US | claimed |
| CN-118845876-A | Aerosol matrix, application thereof and aerosol generating device | 深圳芳芯科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-111053281-A | Flavor composition and electronic cigarette liquid containing same | 深圳雾芯科技有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-107532063-B | Methylmenthol derivative and cold-sensitive composition containing the same | 高砂香料工业株式会社 | 2020-03-10 | — | — | CN | claimed |
| CN-101400408-A | Compositions and methods for eliminating oral malodour | GIVAUDAN SA (CH) | 2009-04-01 | — | — | CN | claimed |
| CN-101394897-A | Compositions and methods to counteract oral malodour | GIVAUDAN SA (CH) | 2009-03-25 | — | — | CN | claimed |
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-12-18 | — | — | US | claimed |
| US-20080247966-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-10-09 | — | — | US | claimed |
| EP-1937365-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-07-02 | — | — | EP | claimed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007025402-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | TAS2R60, TAS2R40, LPO | CHRM2 1469/4885CHRM1 1086/4885CHRM4 2272/4885 |
| US-20240358611-A1 | COMPOSITIONS | AZI2, NISCH, CIP2A | CHRM2 2452/4885CHRM1 2104/4885CHRM4 1824/4885 |
| US-20250352444-A1 | Antimicrobial mixtures | LRBA, MGLL, TAS2R50 | CHRM2 4594/4885CHRM1 4395/4885CHRM4 4412/4885 |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | RBP4, LRAT, RARB | CHRM2 1752/4885CHRM1 1989/4885CHRM4 1228/4885 |
| US-20250325463-A1 | COMPOSITIONS (III) | NISCH, TAS1R3, TAS2R3 | CHRM2 2196/4885CHRM1 1618/4885CHRM4 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.